Comparison of the properties of metabolites of CCNU

Wheeler, G.P.; Johnston, T.P.; Bowdon, B.J.; McCaleb, G.S.; Hill, D.L.; Montgomery, J.A.

Biochemical Pharmacology 26(24): 2331-2336

1977


ISSN/ISBN: 0006-2952
PMID: 145865
DOI: 10.1016/0006-2952(77)90436-1
Accession: 068522064

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Properties of the 6 isomeric N-(2-chloroethyl-N'-(hydroxycyclohexyl-N-nitrosoureas which were identified by other investigators as metabolites of N-(2-chloroethyl-N'-cyclohexyl-N-nitrosourea (CCNU), were compared with those of CCNU and 2-[[[(2-chloroethyl)nitrosoamino]-carbonyl]amino]-2-deoxy-D-glucose (chlorozotocin). There are significant differences in the physicochemical, chemical and biological properties of these metabolites, and the properties of some of them are significantly different from those of CCNU and chlorozotocin. The position of the hydroxy group and the steric configuration of the compound markedly affect the alkylating and carbamoylating activities of the compounds. Metabolites having higher alkylating activities and lower carbamoylating activities produce lethal toxicity to mice at lower molar doses but have somewhat better therapeutic indexes. The data are consistent with the hypothesis that the biological effects observed following the administration of CCNU are due to a large extent to the major metabolites with lesser effects contributed by minor metabolites. Some of the metabolites have slightly better therapeutic indexes against murine leukemia L1210 than CCNU and chlorozotocin, and they are more soluble in water than CCNU but are active against i.p. and intracerebrally implanted L1210 leukemia. There might be some therapeutic advantage to administering 1 of the minor metabolities instead of CCNU or chlorozotocin to cancer-bearing animals.